Anti-angiogenic therapy in breast cancer

Biomedicine and Pharmacotherapy

Volumn 57, Issue 10, 2003, Pages 463-470

  Rahman, Mohammad Atiqur ^a   Toi, Masakazu ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Angiogenesis; Breast cancer; Cancer prevention; COX 2; VEGF

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLSALICYLIC ACID; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FIBROBLAST GROWTH FACTOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; BREAST CANCER; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; DRUG ACTIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INDUCTION; GENE OVEREXPRESSION; HORMONE SENSITIVITY; HUMAN; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0344443297     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2003.09.009     Document Type: Article

References (73)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med. 1:1995;27-31.
2. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. J Cell. 86:1996;353-364.
3. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:1990;4-6.
4. Oshima M., Dinchuk J.E., Kargman S.L., et al. Suppression of intestinal polyposis in APC knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809.
5. Steinbach G., Lynch P.M., Phillips R.K., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor in familial adenomatous polyposis. New Engl J Med. 342:2000;1946-1952.
6. Susan B.A., Ari R., Karen N., et al. Structure of the human cyclo-oxygenase-2 gene. Biochem J. 302:1994;723-727.
7. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 84:1992;1875-1887.
8. Toi M., Kashitani J., Tominaga T. Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. Int J Cancer. 55:1993;371-374.
9. Widner N., Semple J.P., Welch W.R., Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. New Engl J Med. 324:1991;1-8.
10. Weidner N., Folkman J., Pozza F., Bevilacqua P., Allred E.N., Moore D.H., et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 84:1992;1875-1887.
11. Hork E.R., Leek R., Klenk N., Lejeune S., Smith K., Stuart N., et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 340:1992;1120-1124.
12. Toi M., Inada K., Suzuki H., Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat. 36:1995;193-204.
13. Costa C., Soares R., Reis-Filho J.S., Leitao D., Amendoeira I., Schmitt F.C. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol. 55:2002;429-434.
14. Sheng H., Shao J., Dubois R.N. K-Ras-mediated increase in cyclooxygenase-2 mRNA stability involves activation of the protein kinase B1. Cancer Res. 61:2001;2670-2675.
15. Keene J.D. Why is Hu where? Shuttling of early-response-gene messenger RNA subsets. Proc Natl Acad Sci USA. 96:1999;5-7.
16. Dan A.D., Neal D.T., Peter H.K., et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest. 108:2001;1657-1665.
17. Lowell G.S., Wan Z., Stephen W.S. Androgen regulates the level and subcellular distribution of the AU-rich ribonucleic acid-binding protein HuR both in vitro and in vivo. Endocrinology. 142:2001;2361-2368.
18. Lu D., Jimenez X., Zhang H., Bohlen P., Witte L., Zhu Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer. 97:2002;393-399.
19. Niethammer A.G., et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 8:2002;1369-1375.
20. O'Reilly M.S. Vessel maneuvers: vaccine targets tumor vasculature. Nat Med. 8:2002;1352-1353.
21. Toi M., Matsumotom T., Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2:2001;667-673.
22. Toi M., Bando H., Ogawa T., Muta M., Hornig C., Weich H.A. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer. 98:2002;14-18.
23. Brekken R.A., Overholser J.P., Stastny V.A., et al. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. 60:2000;5117-5124.
24. Klement G., Baruchel S., Rak J., et al. Continuous low-dose therapy with vinblastin and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 105:2000;R15-R24.
25. Kawasaki T., Kitsukawa T., Bekku Y., Matsuda Y., Sanbo M., Yagi T., et al. A requirement for neuropilin-1 in embryonic vessel formation. Development. 126:1999;4895-4902.
26. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropi-lin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 92:1998;735-745.
27. Whitaker G.B., Limberg B.J., Rosenbaum J.S. Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of vegf165 and vegf121. J Biol Chem. 276:2001;25520-25531.
28. Matthies A.M., Low Q.E., Lingen M.W., DiPietro L.A. Neuropilin-1 participates in wound angiogenesis. Am J Pathol. 160:2002;289-296.
29. Smits A., Funa K., Vassbotin F.S., Beausang-Linder M., Af-Ekenstam F., Heldin C.H., et al. Expression of platelet-derived growth factor and its receptors in proliferative disorders of fibroblastic origin. Am J Pathol. 140:1992;639-648.
30. Marc D.C., Jain W., Peggy L.P., Allen M.G. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res. 55:1995;2703-2708.
31. Peilin Z., Wei Y.G., Steven T., Barbara S.D. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer. 2:2003;2-9.
32. Toi M., Harris A.L., Bicknell R. Interleukin-4 is a potent mitogen for capillary endothelium. Biochem Biophys Res Commun. 174:1991;1287-1293.
33. Ueno T., Toi M., Saji H., et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 6:2000;3282-3289.
34. Toi M., Ueno T., Matsumoto H., et al. Significance of thymidine phosphorylase as a marker of protumor monocytes in breast cancer. Clin Cancer Res. 5:1999;1131-1137.
35. Sivridis E., Giatromanolaki A., Anastasiadis P., Georgiou L., Gatter K.C., Harris A.L., et al. Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. J Pathol. 196:2002;416-422.
36. Kirkpatrick K., Ogunkolade W., Elkak A., Bustin S., Jenkins P., Ghilchik M., et al. The mRNA expression of cyclo-oxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr Med Res Opin. 18:2002;237-241.
37. Carmeliet P.D., Herbert J.M., et al. Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature. 394:1998;485-490.
38. Liu X.H. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem. 277:2002;50081-50086.
39. Rudnick D.A., Perlmutter D.H., Muglia L.J. Prostaglandins are required for CREB activation and cellular proliferation during liver regeneration. Proc Natl Acad Sci USA. 98:2001;8885-8890.
40. Tortora G., Caputo R., Damiano V., Melisi D., Bianco R., Fontanini G., et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res. 9:2003;1566-1572.
41. Lipponen P., Ji H., Aaltomaa S., Syrjanen K. Tumour vascularity and basement membrane structure in breast cancer as related to tumour histology and prognosis. J Cancer Res Clin Oncol. 120:1994;645-650.
42. Hung W.C., Chang H.C., Pan M.R., et al. Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol Pharmacol. 58:2000;1398-1403.
43. Leivonen M., Nordling S., Lundin J., von Boguslawski K., Haglund C. p27 expression correlates with short-term, but not with long-term prognosis in breast cancer. Breast Cancer Res Treat. 67:2001;15-22.
44. Subbaramaiah K., Norton L., Gerald W., Dannenberg A.J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem. 277:2002;18649-18657.
45. Tsujii M., Dubois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 83:1995;493-501.
46. Pedersen K.B., Nesland J.M., Fodstad O., Maelandsmo G.M. Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies. Br J Cancer. 87:2002;1281-1286.
47. Masferrer J.L., Koki A., Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci. 889:1999;84-86.
48. Achiwa H., Yatabe Y., Hida T., et al. Prognostic significance of elevated cyclooxygenase-2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res. 5:1999;1001-1005.
49. Masunaga R., Kohno H., Dhar D.K., et al. COX-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res. 6:2000;4064-4068.
50. Marnett L.J. Aspirin and the potential role of prostaglandin in colon cancer. Cancer Res. 52:1992;5575-5589.
51. Subbegowda R., Frommel T.O. Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. Cancer Res. 58:1998;2772-2776.
52. Edward G., Eric B.R., Meir J.S., et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Int Med. 121:1994;241-246.
53. Dubois R.N. Cyclooxygenase-2 a target for colon cancer prevention. Aliment Pharmacol Ther. 14:2000;64-67.
54. Hsu A.L., Ching T.T., Wang D.S., et al. The cyclooxygenase-2 inhibitor celecoxib induce apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 275:2000;11397-11403.
55. Kawamori T., Rao C.V., Seibert K., et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412.
56. Goshi N., Syunsuke Y., Hiromi M., et al. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res. 90:1999;1152-1162.
57. Pentland A.P., Schoggins J.W., Scott G.A., et al. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis. 20:1999;1939-1944.
58. Grubbs C.J., Lubet R.A., Koki A.T., et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60:2000;5599-5602.
59. Masferrer J.L., Leahy K.M., Koki A.T., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306-1311.
60. Liu X.H., Kirschenbaum A., Yao S., et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 164:2000;820-825.
61. Chang H.C., Weng C.F. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol Rep. 8:2001;1321-1325.
62. Williams C.S., Sheng H., Brockman J.A., et al. A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia. 3:2001;428-436.
63. Abiru S., Nakao K., Ichikawa T., et al. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology. 35:2002;1117-1124.
64. Callejas N.A., Casado M., Bosca L., et al. Absence of nuclear factor κB inhibition by NSAIDs in hepatocytes. Hepatology. 35:2002;341-348.
65. Zhu W., Smith A., Young C.Y. A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology. 140:1999;5451-5454.
66. Cotroneo M.S., Wang J., Fritz W.A., Eltoum I.E., Lamartiniere C.A. Genistein action in the prepubertal mammary gland in a chemoprevention model. Carcinogenesis. 23:2002;1467-1474.
67. Buchholz T.A., Wu X., Hussain A., Tucker S.L., Mills G.B., Haffty B., et al. Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. Int J Cancer. 97:2002;557-561.
68. Zhang Z., Dubois R.N. Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology. 118:2000;1012-1017.
69. Dempke W., Rie C., Grothey A., Schmoll H.J. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 127:2001;411-417.
70. Kojima M., Morisaki T., Uchiyama A., et al. Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas. Ann Surg Oncol. 8:2001;458-465.
71. Nuria A.C., Amalia F.M., Antonio C., Lisardo B., Paloma M.S. Selective inhibitors of cyclooxygenase-2 delay the activation of nuclear factor κB and attenuate the expression of inflammatory genes in murine macrophages treated with lipopolysaccharide. Mol Pharmacol. 63:2003;671-677.
72. Hajitou A., Grignet C., Devy L., Berndt S., Blacher S., Deroanne C.F., et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 16:2002;1802-1804.
73. Calvo A., Yokoyama Y., Smith L.E., Ali I., Shih S.C., Feldman A.L., et al. Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer. 101:2002;224-234.